Blog
RSS FeedPosted by Michael Wonder on 30 Aug 2016
CADTH recommends Brilinta (ticagrelor)
25 August 2016 - CADTH has recommended the reimbursement of AstraZeneca's Brilinta (ticagrelor) for the secondary prevention of atherothrombotic events. ...
Posted by Michael Wonder on 29 Aug 2016
CADTH recommends against the reimbursement of Egrifta (tesamorelin acetate)
24 August 2016 - CADTH is not convinced that Egrifta should be reimbursed in Canada. ...
Posted by Michael Wonder on 29 Aug 2016
CADTH recommends the reimbursement of Descovy (emtricitabine with tenofovir alafenamide fumarate)
24 August 2016 - CADTH is in favour of the reimbursement of Gilead's new dual combination product for HIV-1 infection. ...
Posted by Michael Wonder on 28 Aug 2016
CADTH recommends reimbursement of secukinumab (Cosentyx) for ankylosing spondylitis
23 August 2016 - CADTH publishes second outcome for Cosentyx this month. ...
Posted by Michael Wonder on 28 Aug 2016
CADTH recommends reimbursement of Truvada for PrEP
24 August 2016 - The recommendation comes with conditions. ...
Posted by Michael Wonder on 26 Aug 2016
New Brunswick includes Lemtrada (alemtuzumab) on provincial drug program for eligible patients
25 August 2016 - Unique treatment delivered in only two cycles one year apart. ...
Posted by Michael Wonder on 25 Aug 2016
CADTH recommends the reimbursement of secukinumab (Cosentyx) for psoriatic arthritis
23 August 2016 - CADTH has issued a final recommendation on the reimbursement of secukinumab (Cosentyx) for patients with psoriatic ...
Posted by Michael Wonder on 12 Aug 2016
CADTH calls for patient input on submission from Janssen for Stelara (ustekinumab)
12 August 2016 - CADTH has received notice of a pending submission from Janssen for ustekinumab for use by patients with ...
Posted by Michael Wonder on 11 Aug 2016
CADTH provides an update on its therapeutic review of new drugs for type 2 diabetes mellitus
10 August 2016 - CADTH is undertaking a project to assess the clinical and cost-effectiveness of new drugs for the treatment ...
Posted by Michael Wonder on 06 Aug 2016
CADTH calls for patient input on a submission from Cipher Pharmaceuticals for Actikerall (5-fluorouracil with salicylic acid)
5 August 2016 - CADTH is calling for patient input on a pending submission from Cipher Pharmaceuticals for Actikerall. ...
Posted by Michael Wonder on 03 Aug 2016
CADTH calls for patient input on a submission from Horizon Pharmaceuticals for Ravicti (glycerol phenylbutyrate)
2 August 2016 - CADTH has called for patient input from Horizon Pharmaceuticals for Ravicti. ...
Posted by Michael Wonder on 03 Aug 2016
CADTH calls for patient input on submission from Allergan for Fetzima (levomilnacipran hydrochloride)
2 August 2016 - CADTH is calling for patient input on a pending submission from Allergan for Fetzima. ...
Posted by Michael Wonder on 31 Jul 2016
CADTH recommends reimbursement of Eylea
27 July 2016 - CADTH has recommended that Bayer's aflibercept (Eylea) be reimbursed in Canada. ...
Posted by Michael Wonder on 30 Jul 2016
CADTH recommends reimbursement of Revestive
29 July 2016 - CADTH has recommended that Shire's teduglutide (Revestive) be reimbursed in Canada. ...
Posted by Michael Wonder on 27 Jul 2016
CADTH calls for patient input on submission from Pierre Fabre for Hemangiol (propranolol hydrochloride)
27 July 2016 - CADTH has received notice of a pending submission from Pierre Fabre for Hemangiol (propranolol hydrochloride). ...